OptimizeRx (NASDAQ:OPRX) Raised to "Buy" at Wall Street Zen

Wall Street Zen upgraded shares of OptimizeRx (NASDAQ:OPRX - Free Report) from a hold rating to a buy rating in a research report sent to investors on Thursday.

A number of other research firms have also commented on OPRX. JMP Securities raised their price objective on OptimizeRx from $11.00 to $14.00 and gave the stock a "market outperform" rating in a research note on Tuesday, May 13th. Citigroup restated an "outperform" rating on shares of OptimizeRx in a research note on Tuesday, May 13th. Roth Capital restated a "buy" rating on shares of OptimizeRx in a research note on Tuesday, May 13th. B. Riley restated a "buy" rating on shares of OptimizeRx in a research note on Tuesday, May 13th. Finally, Stifel Nicolaus raised their price objective on OptimizeRx from $8.00 to $12.50 and gave the stock a "buy" rating in a research note on Tuesday, May 13th. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, OptimizeRx has an average rating of "Moderate Buy" and a consensus price target of $10.38.

OptimizeRx Stock Performance

Shares of OptimizeRx stock traded up $0.98 on Thursday, hitting $12.63. The stock had a trading volume of 239,094 shares, compared to its average volume of 279,240. OptimizeRx has a twelve month low of $3.78 and a twelve month high of $13.00. The business's 50 day moving average is $9.22 and its two-hundred day moving average is $6.75. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 0.29. The stock has a market cap of $233.50 million, a price-to-earnings ratio of -9.46 and a beta of 1.28.

OptimizeRx (NASDAQ:OPRX - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported $0.08 EPS for the quarter, beating the consensus estimate of ($0.11) by $0.19. OptimizeRx had a negative return on equity of 4.92% and a negative net margin of 27.41%. The company had revenue of $21.93 million for the quarter, compared to the consensus estimate of $18.69 million. Analysts forecast that OptimizeRx will post -0.33 EPS for the current year.

Insider Buying and Selling at OptimizeRx

In other news, Director James Paul Lang acquired 321,408 shares of the business's stock in a transaction that occurred on Friday, March 14th. The shares were bought at an average price of $7.60 per share, with a total value of $2,442,700.80. Following the acquisition, the director now directly owns 389,452 shares in the company, valued at $2,959,835.20. The trade was a 472.35% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 5.60% of the company's stock.

Institutional Investors Weigh In On OptimizeRx

Hedge funds have recently modified their holdings of the company. SBI Securities Co. Ltd. acquired a new stake in shares of OptimizeRx during the 4th quarter valued at $25,000. GAMMA Investing LLC acquired a new stake in shares of OptimizeRx during the 1st quarter valued at $33,000. SG Americas Securities LLC acquired a new stake in shares of OptimizeRx during the 4th quarter valued at $51,000. Wells Fargo & Company MN boosted its holdings in shares of OptimizeRx by 33.3% during the 4th quarter. Wells Fargo & Company MN now owns 11,208 shares of the company's stock valued at $54,000 after acquiring an additional 2,797 shares in the last quarter. Finally, Graham Capital Management L.P. acquired a new stake in shares of OptimizeRx during the 4th quarter valued at $81,000. Institutional investors and hedge funds own 76.47% of the company's stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.